New combo aims to shrink hard-to-treat breast tumors

NCT ID NCT07368998

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This study tests two different doses of inavolisib combined with fulvestrant in people with a specific type of advanced breast cancer (PIK3CA-mutated, HR-positive, HER2-negative). About 80 participants whose cancer worsened after prior treatment will receive the drug combo. The goal is to see if a lower dose works as well with fewer side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Adana Baskent University Hospital
RECRUITING

Adana, 01120, Turkey (Türkiye)
Astera Cancer Care East Brunswick
RECRUITING

East Brunswick, New Jersey, 08816, United States
Bagcilar Medipol Mega Universitesi Hastanesi
RECRUITING

Bağcılar, Istanbul, 34214, Turkey (Türkiye)
Bendigo Cancer Centre
RECRUITING

Bendigo, Victoria, 3550, Australia
Blackpool Victoria Hospital
RECRUITING

Blackpool, FY3 8NR, United Kingdom
Blacktown Hospital
RECRUITING

Blacktown, New South Wales, NSW 2148, Australia
CENEIT Oncologicos
RECRUITING

Mexico City, 03100, Mexico
Cancer Specialists of North Florida
RECRUITING

Jacksonville, Florida, 32256, United States
Centro Oncologico Korben
RECRUITING

Ciudad Autonoma Buenos Aires, C1426AGE, Argentina
Centro Oncologico Riojano Integral (CORI)
RECRUITING

La Rioja, F5300COE, Argentina
Centro Oncológico de Excelencia
RECRUITING

San Juan, J5402BGA, Argentina
Centro de Infusion Tratamiento e Investigacion Oncologica S DE R
RECRUITING

Queretaro Qro, Querétaro, 76090, Mexico
Clinique Ste-Elisabeth
RECRUITING

Namur, 5000, Belgium
Cliniques Universitaires St-Luc
RECRUITING

Brussels, 1200, Belgium
Coffs Harbour Health Campus
RECRUITING

Coffs Harbour, New South Wales, 2450, Australia
Hospital Civil de Guadalajara Fray Antonio Alcalde
RECRUITING

Guadalajara, Jalisco, 44280, Mexico
Hospital Clinico Universitario de Valencia
RECRUITING

Valencia, 46010, Spain
Hospital Privado - Centro Medico de Córdoba
RECRUITING

Córdoba, 5016, Argentina
Hospital Provincial del Centenario
RECRUITING

Rosario, S2002KDS, Argentina
Hospital Universitari Vall d'Hebron;Oncology
RECRUITING

Barcelona, 08035, Spain
Hospital Universitario 12 De Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario San Cecilio
RECRUITING

Granada, 18016, Spain
Instituto de Oncologia de Rosario
RECRUITING

Rosario, Santa Fe Province, S2000KPG, Argentina
Jessa Zkh (Campus Virga Jesse)
RECRUITING

Hasselt, 3500, Belgium
Los Angeles Cancer Network
RECRUITING

Los Angeles, California, 90017-4803, United States
Medical Park Seyhan Hospital
RECRUITING

Seyhan, Turkey (Türkiye)
Memorial Ankara Hastanesi
RECRUITING

Ankara, 06520, Turkey (Türkiye)
Mount Vernon Cancer Centre
RECRUITING

Northwood, Middlesex, HA6 2RN, United Kingdom
Princess Alexandra Hospital
RECRUITING

Harlow, CM20 1QX, United Kingdom
RENATI INNOVATION S.A.P.I. de C.V
RECRUITING

Guadalajara, Jalisco, 44680, Mexico
UZ Leuven Gasthuisberg
RECRUITING

Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.